Valuation: Altimmune, Inc.

Market Cap 605M 518M 485M 444M 833M 57.88B 844M 5.73B 2.23B 29.08B 2.27B 2.22B 96.17B P/E 2026 *
-5.31x
P/E 2027 * -4.74x
Enterprise Value 164M 141M 132M 121M 226M 15.73B 229M 1.56B 607M 7.9B 617M 604M 26.14B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.58%
Yield 2026 *
-
Yield 2027 * -
1 day+5.42%
1 week+5.78%
Current month+9.51%
1 month+10.68%
3 months+7.24%
6 months-29.00%
Current year-13.85%
1 week 2.9
Extreme 2.9
3.24
1 month 2.76
Extreme 2.76
3.31
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
8/13/26 A Buy

Chief Executive Officer

15,000 0.0077%
7/31/26 A Free

Chief Financial Officer

1,753 0.0009%
7/31/26 A Free

Chief Technology Officer

875 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+5.42%+5.78%-12.15%+20.54% 605M
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.67%+8.11%+51.97%+179.97% 29.01B
Weighted average by Cap. +0.75%+9.47%+57.88%+157.57%

Financials

2026 *2027 *
Net sales - -
Net income -100M -86.08M -80.54M -73.73M -138M -9.61B -140M -952M -371M -4.83B -377M -369M -15.98B -123M -105M -98.71M -90.35M -170M -11.78B -172M -1.17B -455M -5.92B -462M -452M -19.58B
Net Debt -440M -377M -353M -323M -607M -42.15B -615M -4.17B -1.63B -21.17B -1.65B -1.62B -70.03B -332M -284M -266M -243M -457M -31.74B -463M -3.14B -1.22B -15.94B -1.25B -1.22B -52.73B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
21/08/26 $3.110 +5.42% 6,157,414
20/08/26 $2.950 -5.45% 4,681,380
19/08/26 $3.120 +5.05% 10,824,068
18/08/26 $2.970 -1.00% 2,472,114
17/08/26 $3.000 +2.04% 4,056,884
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
3.110USD
Average target price
17.22USD
Spread / Average Target
+453.77%

Quarterly revenue - Rate of surprise